Anebulo develops selonabant, an experimental drug for treating cannabis toxicity, mainly aimed at children and emergency departments. It last closed at $0.28 on Nov 17, up 7.69% on the day. ANEB reports earnings on Wed, Nov 18, 2026.
ANEB · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend
The stock sits between its 20 and 50 day averages. It is 53% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the 20 day average at $0.27, and the nearest resistance the swing high (Nov 9) at $0.29.
Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 13.7%/day
Key levels
$2.4952 week high+789.3%
$0.43200 day average+53.6%
$0.31100 day average+10.7%
$0.2950 day average+3.6%
$0.29Swing high (Nov 9)+3.6%
$0.28Pivot R1+0.0%
$0.28Pivot+0.0%
$0.28Pivot S1+0.0%
$0.28Last close
$0.2720 day average−3.6%
$0.26Swing low (Nov 11)−7.1%
Indicators
RSI (14)
51.55
Middle of its range
Neutral
MACD
0.00
Below its signal line
Bearish
Stochastic
94.2
Near the top of its range
Overbought
ADX (14)
72.8
Strong downtrend
Williams %R
-3.5
Oversold below −80, overbought above −20
Overbought
CCI (20)
51.1
Oversold below −100, overbought above 100
Neutral
Rate of change
+7.7%
Change over 10 sessions
Bullish
ATR (14)
$0.04
Typical daily range, 13.7% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 52.5%/day
Key levels
$2.4952 week high+789.3%
$0.43200 day average+53.6%
$0.31100 day average+10.7%
$0.2950 day average+3.6%
$0.29Swing high (Nov 9)+3.6%
$0.28Pivot R1+0.0%
$0.28Pivot+0.0%
$0.28Pivot S1+0.0%
$0.28Last close
$0.2720 day average−3.6%
$0.26Swing low (Nov 11)−7.1%
Indicators
RSI (14)
43.68
Middle of its range
Neutral
MACD
-0.10
Above its signal line
Bullish
Stochastic
66.2
Middle of its range
Neutral
ADX (14)
43.1
Strong downtrend
Williams %R
-33.4
Oversold below −80, overbought above −20
Neutral
CCI (20)
-8.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−15.5%
Change over 10 sessions
Bearish
ATR (14)
$0.15
Typical daily range, 52.5% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANEB
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ANEB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Earnings in less than a daySignals right before a report are less reliable. The report can override them.
November seasonalityHow ANEB usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ANEB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANEB is in one of them and how their past ANEB trades turned out.
Anebulo Pharmaceuticals is a drug developer based in Lakeway, Texas, working on treatments for cannabis toxicity. Its lead candidate, selonabant, is designed to reverse the effects of cannabis intoxication and shorten recovery time. The company is focused on an intravenous version for children who have been accidentally poisoned by cannabis, with emergency departments as the intended users. Selonabant is still in clinical development and has not been approved for sale.